Paul Cheng, MD
Cardiovascular Disease · Elkhart, INNPI 1124052592
Payments from drug & device makers
Across 144 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$588
- Johnson & Johnson$299
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$171
- Medtronic$140
- Astellas Pharma US Inc$135
- AstraZeneca$104
- plus $863 from 20 others
What the payments were for
- Food & beverage$2,20196%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 49 | $588 |
| Johnson & Johnson | 19 | $299 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $171 |
| Medtronic | 7 | $140 |
| Astellas Pharma US Inc | 3 | $135 |
| AstraZeneca | 8 | $104 |
| Alnylam Pharmaceuticals Inc. | 3 | $93 |
| Amgen | 5 | $92 |
| E.r. Squibb & Sons, L.L.C. | 6 | $84 |
| Sanofi-aventis U.S. LLC | 5 | $84 |
| Actelion Pharmaceuticals US, Inc. | 3 | $70 |
| Amarin Pharma, Inc. | 3 | $45 |
| Boehringer Ingelheim | 3 | $45 |
| Gilead | 3 | $43 |
| Pfizer | 3 | $42 |
| Cardiovascular Systems Inc. | 3 | $40 |
| Chiesi USA, Inc. | 1 | $32 |
| Abbott | 1 | $30 |
| Vifor Pharma, Inc. | 1 | $25 |
| Philips North America LLC | 1 | $25 |
| Cvrx, Inc. | 1 | $25 |
| Bayer | 1 | $21 |
| Convatec Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Heartflow, Inc. | 1 | $15 |
How this compares
$2,301 in reported general payments places this provider in the 45th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 188 | $163,432 |
| XareltoRivaroxaban | 142 | $138,331 |
| EntrestoSacubitril/Valsartan | 39 | $56,509 |
| JardianceEmpagliflozin | 54 | $47,220 |
| FarxigaDapagliflozin Propanediol | 40 | $37,330 |
| BrilintaTicagrelor | 11 | $12,786 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 179 | $4,554 |
| Flecainide Acetate | 94 | $4,389 |
| Felodipine ErFelodipine | 85 | $2,450 |
| Valsartan | 60 | $1,812 |
| Amiodarone Hcl | 40 | $1,527 |
| Metoprolol Succinate | 124 | $1,340 |
| Atorvastatin Calcium | 236 | $1,282 |
| Carvedilol | 152 | $1,172 |
| Rosuvastatin Calcium | 138 | $1,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $42 | $163,432188 claims |
| Johnson & JohnsonXarelto | $299 | $138,331142 claims |
| NovartisEntresto | $588 | $56,50939 claims |
| AstraZenecaFarxiga, Brilinta | $104 | $50,11651 claims |
| Boehringer IngelheimJardiance | $45 | $47,22054 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Elkhart
- Vijay MehtaElkhart$925K
- Wai LeeElkhart$444K
- Troy WeirickElkhart$374K
- Charles MathisElkhart$64K
- John McGintyRichmond$3.7M
- Steven SteinhublLafayette$2.4M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.